Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study

Figures & data

Figure 1 Study design.

Abbreviations: DBP, diastolic blood pressure; OLM, olmesartan; HCTZ, hydrochlorothiazide.

Table 1 Summary of demographic and clinical characteristics

Characteristic	Non-randomized patients	Randomized patients
	Olmesartan 20 mg/day (n = 1546)	Olmesartan 40 mg/day (n = 302)	Olmesartan 20 mg/day + HCTZ 12.5 mg/day (n = 325)
Male, %	50.7	63.2	57.8
Caucasian, %	98.7	97.4	98.5
Body mass index (kg/m^2)	28.4 ± 4.8	29.4 ± 5.2	29.6 ± 5.2
Age (years)	55.1 ± 11.1	54.8 ± 10.9	54.9 ± 10.1
Diabetic, %	5.8	9.9	9.5
Baseline SBP (mmHg)	154.2 ± 13.0	160.8 ± 14.2	160.8 ± 14.0
Baseline DBP (mmHg)	96.6 ± 4.8	100.8 ± 5.6	100.2 ± 5.1

Data for the two randomized groups are reproduced from Barrios V, Boccanelli A, Ewald S, et al. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST study. Clin Drug Investig. 2007;27:545–558¹⁴ with permission from Wolters Kluwer Health | Adis (© Adis Data Information BV 2007. All rights reserved).

Values are mean ± standard deviation, except where indicated.

Abbreviations: DBP, diastolic blood pressure; HCTZ, hydrochlorothiazide; SBP, systolic blood pressure.

Figure 2 Blood pressure (BP) goal achievement rates at Week 12 for (a) combined systolic and diastolic BP (SBP and DBP) goals and for (b) individual SBP and DBP goals.

BarriosVBoccanelliAEwaldSEfficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST studyClin Drug Investig200727 545558

 PubMed Web of Science ®Google Scholar